Comparative effects of atorvastatin and rosuvastatin on inflammatory biomarkers: a systematic review and meta-analysis of randomized head-to-head trials.

Authors

Abu Omayer, Mohamed I Mohamed, Maryam Shahid, Syed Mohammed Hassanul Hoque, Nour Elhuda Ahmed Mostafa Mohamed, Enjy Mohamed Amer Elsayed, Moussa Nassar, Tarique Ahmed, Yasar Sattar

Published in

BMC cardiovascular disorders. Volume 26. Issue 1. Sep 10, 2026. Epub Sep 10, 2026.

Abstract

Inflammation contributes significantly to cardiovascular disease progression. While both atorvastatin and rosuvastatin have anti-inflammatory effects, evidence directly comparing their effects on inflammatory biomarkers is limited and inconsistent. This study aimed to compare their effects through a meta-analysis of randomized controlled trials (RCTs).
We performed a systematic review and meta-analysis of head-to-head RCTs comparing atorvastatin and rosuvastatin on inflammatory biomarkers. On August 14, 2024, we searched PubMed, Web of Science, Scopus, and CENTRAL, and subsequently searched ClinicalTrials.gov for unpublished studies. We included RCTs directly comparing the two statins and reported changes in C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), or adiponectin. Using a random-effects model, we pooled the data and reported the results as mean differences (MD) or standardized mean differences (SMD) with 95% confidence intervals (CIs). We assessed risk of bias using the Cochrane RoB 2 tool. The review protocol was registered in PROSPERO (CRD42024579712) (see the PRISMA 2020 for Abstracts checklist).
A total of 35 RCTs (n = 6,148) were included. The pooled effect showed no significant difference in CRP reduction (MD: - 0.53 mg/L; 95% CI: - 1.10 to 0.05; p = 0.07; I² = 82%). After excluding one outlier, rosuvastatin showed a greater reduction (MD: - 0.16 mg/L; 95% CI: - 0.28 to - 0.03; p = 0.01; I² = 63%). The SMD also favored rosuvastatin (SMD: - 0.17; 95% CI: - 0.31 to - 0.04; p = 0.01). Sensitivity analysis among low risk-of-bias studies (n = 9) showed a smaller yet significant reduction (MD: - 0.08 mg/L; 95% CI: - 0.16 to - 0.01; p = 0.03). We observed no significant differences for IL-6 (n = 484; MD: - 0.82; 95% CI: - 3.02 to 1.38), adiponectin (n = 257; MD: - 1.78; 95% CI: - 4.70 to 1.14), or TNF-alpha (n = 309; MD: 0.23; 95% CI: - 0.05 to 0.52). Meta-regression identified baseline CRP, HDL, and hypertension prevalence as predictors of CRP reduction.
Rosuvastatin showed a modest but statistically significant advantage over atorvastatin in lowering CRP, especially in patients with higher baseline inflammation or hypertension. Evidence for other biomarkers remains inconclusive. Tailoring statin therapy to patient profiles may optimize benefits.

PMID:
42723012
Bibliographic data and abstract were imported from PubMed on 11 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.